DBV Technologies S.A.
DBVT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001613780
In the last 90 days, DBV Technologies S.A. insiders filed 0 open-market purchases and 1 sale; 78 institutions reported holding it in 13F filings for Q2 2026, worth $345.7M in total; Duquesne Family Office is the only superinvestor holding it.
Other share classesDBVTF
Q1 2025 vs. Q4 2024
How the institutions holding DBV Technologies S.A. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 18 | 16 | −2 |
| Shares | 2.74M | 2.47M | −269.2K (−9.8%) |
| Value | $8.46M | $16.8M | +$8.37M (+99.0%) |
New holders (3)
Institutions that held DBV Technologies S.A. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Cantor Fitzgerald, L. P. | 95,460 | $651.0K | 0.02% |
| Toronto Dominion Bank | 320 | $2.18K | 0.00% |
| Advisor Group Holdings, Inc. | 11 | $74 | 0.00% |
Sold out (5)
Institutions that held DBV Technologies S.A. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Point72 Asset Management, L.P. | 286,250 | $884.5K |
| Boxer Capital Management, LLC | 50,000 | $154.5K |
| Vivo Capital, LLC | 32,020 | $98.9K |
| BNP Paribas Arbitrage, SA | 1,650 | $5.10K |
| Bank of America Corp | 123 | $380 |